AbbVie

With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg
With Allergan megamerger looming, AbbVie plots massive $28B bond offering: Bloomberg
Fierce Pharma
AbbVie
Allergan
M&A
Flag link:
AbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL
AbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL
Pharmaceutical Business Review
AbbVie
Imbruvica
rituximab
CLL
SLL
Flag link:
Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Check?
Should You Worry About AbbVie Inc.'s (NYSE:ABBV) CEO Pay Check?
Yahoo/Simply Wall St
Pharma CEOs
AbbVie
Rick Gonzalez
executive pay
Flag link:
AbbVie may count on Allergan's Botox for post-merger growth. But what else?
AbbVie may count on Allergan's Botox for post-merger growth. But what else?
Fierce Pharma
Allergan
AbbVie
M&A
Botox
Flag link:
3 Most Important Takeaways From AbbVie's Q3 Results
3 Most Important Takeaways From AbbVie's Q3 Results
Motley Fool
AbbVie
earnings
Humira
Imbruvica
Flag link:
AbbVie says multiple parties vying for assets related to Allergan deal approval
AbbVie says multiple parties vying for assets related to Allergan deal approval
Yahoo/Reuters
AbbVie
Allergan
Zenprep
brazikumab
M&A
Flag link:
Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say
Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say
Fierce Pharma
AbbVie
Rinvoq
AstraZeneca
Calquence
Imbruvica
Flag link:
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View
Yahoo/Zacks.com
AbbVie
earnings
Flag link:
Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial
Novartis’ Cosentyx Narrowly Misses Beating Out AbbVie’s Humira in Arthritis Trial
BioSpace
Novartis
Cosentyx
AbbVie
Humira
clinical trial
psoriatic arthritis
Flag link:
AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis
AbbVie eyes 2nd Rinvoq nod as it hits its marks in psoriatic arthritis
Fierce Pharma
AbbVie
Rinvoq
FDA
psoriatic arthritis
Flag link:
AbbVie (ABBV) Set to Report Q3 Results: Can Things Turnaround?
AbbVie (ABBV) Set to Report Q3 Results: Can Things Turnaround?
Yahoo/Zacks.com
AbbVie
earnings
Flag link:
Disc Medicine nabs cash, big backers and biopharma drug deal
Disc Medicine nabs cash, big backers and biopharma drug deal
Fierce Biotech
Disc Medicine
AbbVie
Novo Nodisk
monoclonal antibodies
Flag link:
State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny
State-Pharma Deals for Hepatitis C Drugs Come Under Scrutiny
BioSpace
hepatitis C
Washington state
AbbVie
Louisiana
Gilead Sciences
Asegua Therapeutics
Flag link:
Cystic Fibrosis Foundation Licenses Experimental Compound to AbbVie
Cystic Fibrosis Foundation Licenses Experimental Compound to AbbVie
BioSpace
AbbVie
cystic fibrosis
drug development
Flag link:
AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing
AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing
Fierce Pharma
AbbVie
Rinvoq
Europe
JNJ
Spravato
Flag link:
Another hit for AbbVie: Unexpected $673M Irish tax bill adds to Allergan merger woes
Another hit for AbbVie: Unexpected $673M Irish tax bill adds to Allergan merger woes
Fierce Pharma
Allergan
AbbVie
Ireland
taxes
M&A
Flag link:
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
Fierce Pharma
DTC ads
television ads
AbbVie
Humira
Gilead Sciences
Truvada
Allergan
Botox
Flag link:
AbbVie Stays Busy While Working to Complete Allergan Acquisition
AbbVie Stays Busy While Working to Complete Allergan Acquisition
BioSpace
AbbVie
Allergan
M&A
Skyrizi
Reata Pharmaceuticals
Flag link:
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Flag link:
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Endpoints
AbbVie
Principia Biopharma
PRN1008
pemphigus vulgaris
Flag link:

Pages